NCR Online Journal

Juvenile Rheumatoid Arthritis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eli Lilly and Company, Novartis, Sanofi, Regeneron, AbbVie, Cerecor and Others

 Breaking News
  • No posts were found

Juvenile Rheumatoid Arthritis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eli Lilly and Company, Novartis, Sanofi, Regeneron, AbbVie, Cerecor and Others

May 13
04:28 2021
Juvenile Rheumatoid Arthritis Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Eli Lilly and Company, Novartis, Sanofi, Regeneron, AbbVie, Cerecor and Others

Juvenile Rheumatoid Arthritis Pipeline

Juvenile Rheumatoid Arthritis is the most common chronic rheumatologic disease in children and is one of the most common chronic diseases of childhood. The etiology is unknown, and the genetic component is complex, making clear distinctions between the various subtypes difficult. A new nomenclature, juvenile idiopathic arthritis (JIA), is being increasingly used to provide better definition of subgroups. Symptoms may appear during episodes (flare-ups). Or they may be ongoing (chronic). Each child’s symptoms can vary.

“DelveInsight’s, “Juvenile Rheumatoid Arthritis Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Juvenile Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Some of Juvenile Rheumatoid Arthritis Companies are:

  • Eli Lilly and Company
  • Novartis
  • Sanofi
  • Regeneron
  • AbbVie
  • GeneScience Pharmaceuticals
  • Cerecor
  • Bio-Thera solutions
  • Mycenax Biotech
  • Boehringer Ingelheim
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/juvenile-rheumatoid-arthritis-pipeline-insight

 

DelveInsight’s Juvenile Rheumatoid Arthritis report covers around 10+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Juvenile Rheumatoid Arthritis therapies:

  • Barcitinib
  • AIN 457
  • Sarilumab
  • Upadacitinib
  • Genakumab
  • CERC 007
  • Adalimumab biosimilar
  • Tocilizumab biosimilar
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/juvenile-rheumatoid-arthritis-pipeline-insight

 

Current Juvenile Rheumatoid Arthritis Treatment Scenario and Juvenile Rheumatoid Arthritis Emerging Therapies:

  • How many companies are developing Juvenile Rheumatoid Arthritis drugs?
  • How many Juvenile Rheumatoid Arthritis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Juvenile Rheumatoid Arthritis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Juvenile Rheumatoid Arthritis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Juvenile Rheumatoid Arthritis and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/juvenile-rheumatoid-arthritis-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Juvenile Rheumatoid Arthritis: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Juvenile Rheumatoid Arthritis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Juvenile Rheumatoid Arthritis Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Baricitinib: Eli Lilly and Company

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Sarilumab: Sanofi/Regeneron

Drug profiles in the detailed report…..

Early stage products (Phase I/II)

• Comparative Analysis

Genakumab: GeneScience Pharmaceuticals

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Juvenile Rheumatoid Arthritis Key Companies

Juvenile Rheumatoid Arthritis Key Products

Juvenile Rheumatoid Arthritis- Unmet Needs

Juvenile Rheumatoid Arthritis- Market Drivers and Barriers

Juvenile Rheumatoid Arthritis- Future Perspectives and Conclusion

Juvenile Rheumatoid Arthritis Analyst Views

Juvenile Rheumatoid Arthritis Key Companies

Appendix

Request for Free Sample Report: https://www.delveinsight.com/sample-request/juvenile-rheumatoid-arthritis-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/juvenile-rheumatoid-arthritis-pipeline-insight

Related Articles